Patients with RA diagnosis according to 2010 ACR/EULAR criteria and who were prescribed for the first time a BP among the TNF inhibitors adalimumab, infliximab (original product or biosimilar), etanercept, the anti-CD20 antibody rituximab, or the anti-IL6R antibody tocilizumab (administered SC or intravenously) as first-line or second-line therapy were recruited from March 3, 2014 to June 21, 2016. Patients who were not naive for the biotherapy they were given in the study were excluded.

Primary Purpose
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients (ABI-RA)
Study Types
Description of Cohorts
229 patients (176 female, 53 male) diagnosed with RA.
Informed Consent Given?
Multi-center Study?
Homo sapiens
Number of subjects
rheumatoid arthritis juvenile idiopathic arthritis
Sample Sources
tissue sample
Type of Samples Collected
PBMCs RNA DNA plasma